California Supreme Court Rejects Drug Manufacturer Duty to Innovate
In-house counsel for pharmaceutical and biotech companies with California operations can eliminate a key product liability exposure tied to decisions not to develop or update drug formulations, following the state supreme court’s rejection of a manufacturer duty to innovate.
On August 3, 2026, the California Supreme Court issued a 6-1 ruling in the Gilead Tenofovir Cases, explicitly rejecting the legal theory that drug manufacturers owe a duty of care to patients when deciding whether to develop new drug formulations or update existing products. The decision overturns lower court rulings that had permitted negligence claims against drug makers for failing to innovate, eliminating a high-stakes, novel liability theory that created significant uncertainty for pharmaceutical R&D and product lifecycle planning. In-house counsel for pharma and biotech companies operating in California should update product liability risk assessments and R&D decision documentation practices to reflect the eliminated legal exposure.